ARAY Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.448

Open

0.389

VWAP

0.42

Vol

3.01M

Mkt Cap

49.48M

Low

0.380

Amount

1.25M

EV/EBITDA(TTM)

--

Total Shares

118.78M

EV

138.59M

EV/OCF(TTM)

30.48

P/S(TTM)

0.10

Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.

Show More

Events Timeline

(ET)

2026-02-17

16:30:00

Accuray Files to Sell 7M Shares of Common Stock

2026-02-04 (ET)

2026-02-04

16:20:00

Sees FY26 Adjusted EBITDA of $22M-$25M

2026-02-04

16:20:00

Accuray Reports Q2 Revenue of $102.2M

2025-12-15 (ET)

2025-12-15

17:10:00

Accuray Launches Transformation Plan, Expected Annual Profit Improvement of $25M

2025-11-05 (ET)

2025-11-05

16:15:34

Accuray Announces Q1 EPS of 18 Cents Compared to 4 Cents Last Year

2025-10-20 (ET)

2025-10-20

09:25:52

Accuray Projects Q1 Revenue Between $92.5M and $94M, Exceeding Consensus of $91.35M

2025-10-20

09:23:12

Accuray names Steve La Neve as its new CEO

2025-10-08 (ET)

2025-10-08

07:40:37

Accuray Reports First Patient Treated in Melbourne Using CyberKnife S7 System

2025-09-30 (ET)

2025-09-30

07:38:14

Accuray and University of Wisconsin-Madison Establish Memorandum of Understanding

News

seekingalpha

02-05seekingalpha

Accuray Q2 2026 Earnings Call Insights

seekingalpha

02-03seekingalpha

Accuray Scheduled to Announce Q2 Earnings on February 4th

PRnewswire

01-21PRnewswire

Accuray (NASDAQ:ARAY) to Report Q2 FY2026 Financial Results on February 4, 2026

PRnewswire

2025-12-15PRnewswire

Accuray Initiates Strategic Transformation Plan Expected to Boost Annual Profit by $25 Million

Newsfilter

2025-12-15Newsfilter

Accuray Announces $25 Million Profit Improvement Plan with 15% Workforce Reduction

Benzinga

2025-11-06Benzinga

BTIG Reaffirms Buy Rating on Accuray, Reduces Price Target to $4

1 Analyst Rating

Wall Street analysts forecast ARAY stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

BTIG

Buy

downgrade

$4 -> $2

AI Analysis

2026-02-05

Reason

BTIG

Price Target

$4 -> $2

AI Analysis

2026-02-05

downgrade

Buy

Reason

BTIG lowered the firm's price target on Accuray to $2 from $4 and keeps a Buy rating on the shares. The firm cites the company's sales and EBITDA cut on geopolitical pressures, the analyst tells investors in a research note.

BTIG

Buy

maintain

$4 -> $5

2025-08-14

Reason

BTIG

Price Target

$4 -> $5

2025-08-14

maintain

Buy

Reason

BTIG raised the firm's price target on Accuray to $5 from $4 and keeps a Buy rating on the shares. The company's Q4 sales beat was driven by $70.7M in Product revenue and the firm applauds Accuray's ability to execute through a hectic final quarter in FY25, as shipments to China were essentially halted at the start of the quarter and then resumed in May with tariff rates easing, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARAY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Accuray Inc (ARAY.O) is -8.49, compared to its 5-year average forward P/E of 29.11. For a more detailed relative valuation and DCF analysis to assess Accuray Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

29.11

Current PE

-8.49

Overvalued PE

155.27

Undervalued PE

-97.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

15.16

Current EV/EBITDA

6.05

Overvalued EV/EBITDA

22.50

Undervalued EV/EBITDA

7.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

0.58

Current PS

0.20

Overvalued PS

0.82

Undervalued PS

0.34

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stock to buy under 1$ for 2026

Intellectia · 9 candidates

Market Cap: >= 20.00MPrice: <= $1.00Beta: ModerateRisk, HighRiskWeekly Average Turnover: >= 300,000Annual Revenue Yoy Growth: >= 0.0%

Ticker

Name

Market Cap$

Strive Inc

1.11B

Canaan Inc

498.64M

agilon health inc

395.14M

Ring Energy Inc

203.08M

Incannex Healthcare Inc

123.43M

Accuray Inc

91.78M

Whales Holding ARAY

Trading Trends

People Also Watch

Frequently Asked Questions

What is Accuray Inc (ARAY) stock price today?

The current price of ARAY is 0.4166 USD — it has increased 12.42

What is Accuray Inc (ARAY)'s business?

Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.

What is the price predicton of ARAY Stock?

Wall Street analysts forecast ARAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARAY is2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Accuray Inc (ARAY)'s revenue for the last quarter?

Accuray Inc revenue for the last quarter amounts to 102.24M USD, decreased -11.99

What is Accuray Inc (ARAY)'s earnings per share (EPS) for the last quarter?

Accuray Inc. EPS for the last quarter amounts to -0.11 USD, decreased -650.00

How many employees does Accuray Inc (ARAY). have?

Accuray Inc (ARAY) has 990 emplpoyees as of March 16 2026.

What is Accuray Inc (ARAY) market cap?

Today ARAY has the market capitalization of 49.48M USD.